Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Harvard Business School
Cantor Fitzgerald
Deloitte
Fuji
Covington
Baxter
Boehringer Ingelheim
Healthtrust

Generated: February 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,308,329

« Back to Dashboard

Which drugs does patent 9,308,329 protect, and when does it expire?

Patent 9,308,329 protects ADLYXIN and is included in one NDA.

This patent has twenty-one patent family members in sixteen countries.
Summary for Patent: 9,308,329
Title:Medication delivery device and method for operating a medication delivery device
Abstract: A medication delivery device comprises a housing having a proximal end (P) and a distal end (D), a cartridge for holding a medication (M), the cartridge having an outlet, a moveable piston being retained within the cartridge, a drive member moveable in a proximal direction with respect to the housing for setting a dose of medication (M) to be delivered and in the distal direction with respect to the housing for delivering the dose and a piston rod adapted to drive the piston in a distal direction with respect to the cartridge for delivering the dose. The drive member is releasably coupled to the piston rod. The medication delivery device further comprises a resilient member which is arranged to move the drive member in the proximal direction with respect to the housing after dose delivery, thereby reducing pressure of the piston rod on the piston.
Inventor(s): Boyd; Malcolm (Warwickshire, GB), Veasey; Robert (Warwickshire, GB), Plumptre; David (Worcestershire, GB)
Assignee: Sanofi-Aventis Deutschland (Frankfurt am Main, DE)
Application Number:13/131,520
Patent Claim Types:
see list of patent claims
Delivery; Device; Use;

Drugs Protected by US Patent 9,308,329

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-001 Jul 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Try a Free Trial
Sanofi-aventis Us ADLYXIN lixisenatide SOLUTION;SUBCUTANEOUS 208471-002 Jul 27, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 9,308,329

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
08020871Dec 2, 2008
PCT Information
PCT FiledDecember 01, 2009PCT Application Number:PCT/EP2009/066129
PCT Publication Date:June 10, 2010PCT Publication Number: WO2010/063707

Non-Orange Book US Patents Family Members for Patent 9,308,329

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,475,414 Medication delivery device and method for operating a medication delivery device ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,308,329

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 201023931 ➤ Try a Free Trial
Singapore 171861 ➤ Try a Free Trial
Russian Federation 2514114 ➤ Try a Free Trial
Russian Federation 2011127148 ➤ Try a Free Trial
New Zealand 593153 ➤ Try a Free Trial
Mexico 2011004741 ➤ Try a Free Trial
South Korea 101680577 ➤ Try a Free Trial
South Korea 20110096556 ➤ Try a Free Trial
Japan 5581330 ➤ Try a Free Trial
Japan 2012510326 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Queensland Health
US Department of Justice
Citi
Merck
Argus Health
Accenture
Julphar
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot